Real-world experience with ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin in HCV infection

被引：19
|
作者：
Pogorzelska, Joanna [1 ]
Flisiak, Robert [1 ]
机构：
[1] Med Univ Bialystok, Dept Infect Dis & Hepatol, 14 Zurawia St, PL-15540 Bialystok, Poland
来源：
CLINICAL AND EXPERIMENTAL HEPATOLOGY | 2016年 / 2卷 / 02期
关键词：
HCV; paritaprevir; ombitasvir; dasabuvir;
D O I：
10.5114/ceh.2016.60247
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin (OBV/PTV/r +/- DSV +/- RBV) is a new direct-acting antiviral (DAA) regimen which has improved efficacy of chronic hepatitis C virus (HCV) treatment significantly. OBV/PTV/r +/- DSV +/- RBV in clinical trials demonstrated sustained viral response (SVR) rates close to 100%. In this article we collected currently available data of 5726 patients for evaluation of OBV/PTV/r +/- DSV +/- RBV efficacy and safety in real-world experience. The sustained viral response rate in this large population was 97%, and it was exactly the same even in patients with liver cirrhotics. According to this meta-analysis, less than 3% of patients discontinued treatment due to adverse events.
引用
收藏
页码：34 / 37
页数：4
相关论文
共 50 条
  • [41] Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis
    Jingjing Wu
    Peng Huang
    Haozhi Fan
    Ting Tian
    Xueshan Xia
    Zuqiang Fu
    Yan Wang
    Xiangyu Ye
    Ming Yue
    Yun Zhang
    Virology Journal, 16
  • [42] Safety assessment in Child A cirrhotic patients treated with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin
    Manea, E. D.
    Stefan, I
    Olariu, C.
    Calina, O. C.
    Jipa, R. E.
    Hristea, A.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2018, 81 (01) : 9 - 13
  • [43] Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma
    Krastev, Zahariy
    Jelev, Deian
    Antonov, Krasimir
    Petkova, Tanya
    Atanasova, Evelina
    Zheleva, Nadezhda
    Tomov, Bojidar
    Boyanova, Yana
    Mateva, Lyudmila
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (08) : 2630 - 2635
  • [44] Impact of Comorbidities and Comedications on the Effectiveness of Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir ± Ribavirin in Clinical Practice: Real-World Evidence From a Multicountry Postmarketing Observational Study
    Bourgeois, Stefan
    Curescu, Manuela G.
    Larrey, Dominique G.
    Marra, Fiona
    Dorr, Patrick
    Charafeddine, Mariem
    Crown, Eric
    Bondin, Mark
    Back, David J.
    HEPATOLOGY, 2017, 66 : 852A - 852A
  • [45] Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis
    Wu, Jingjing
    Huang, Peng
    Fan, Haozhi
    Tian, Ting
    Xia, Xueshan
    Fu, Zuqiang
    Wang, Yan
    Ye, Xiangyu
    Yue, Ming
    Zhang, Yun
    VIROLOGY JOURNAL, 2019, 16
  • [46] Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma
    Zahariy Krastev
    Deian Jelev
    Krasimir Antonov
    Tanya Petkova
    Evelina Atanasova
    Nadezhda Zheleva
    Bojidar Tomov
    Yana Boyanova
    Lyudmila Mateva
    World Journal of Gastroenterology, 2016, (08) : 2630 - 2635
  • [47] Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America
    Mendizabal, Manuel
    Haddad, Leila
    Gallardo, Patricia E.
    Ferrada, Alejandro
    Soza, Alejandro A.
    Adrover, Raul
    Aravena, Edmundo
    Roblero, Juan P.
    Prieto, Jhon
    Vujacich, Claudia
    Romero, Gustavo
    Munoz, Alberto
    Anders, Margarita
    Hernandez, Nelia
    Coccozella, Daniel
    Gruz, Fernando
    Reggiardo, Maria V.
    Ruf, Andres E.
    Varon, Adriana
    Cartier, Mariano
    Perez Ravier, Roberto
    Ridruejo, Ezequiel
    Peralta, Mirta
    Poncino, Daniel
    Vorobioff, Julio
    Aballay Soteras, Gabriel
    Silva, Marcelo O.
    JOURNAL OF MEDICAL VIROLOGY, 2017, 89 (09) : 1590 - 1596
  • [48] Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia
    Forns, Xavier
    Poordad, Fred
    Pedrosa, Marcos
    Berenguer, Marina
    Wedemeyer, Heiner
    Ferenci, Peter
    Shiffman, Mitchell L.
    Fried, Michael W.
    Lovell, Sandra
    Trinh, Roger
    Lopez-Talavera, Juan Carlos
    Everson, Gregory
    LIVER INTERNATIONAL, 2015, 35 (11) : 2358 - 2362
  • [49] Real-world efficacy and safety of Ledipasvir plus Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience
    Degertekin, Bulent
    Demir, Mehmet
    Akarca, Ulus S.
    Kani, Haluk Tarik
    Ucbilek, Enver
    Yildirim, Emre
    Guzelbulut, Fatih
    Balkan, Ayhan
    Vatansever, Sezgin
    Danis, Nilay
    Demircan, Melek
    Soylu, Aliye
    Yaras, Serkan
    Kartal, Aysun
    Kefeli, Ayse
    Gunduz, Feyza
    Yalcin, Kendal
    Erarslan, Elife
    Aladag, Murat
    Harputluoglu, Murat
    Ozakyol, Aysegul
    Temel, Tuncer
    Akarsu, Mesut
    Sumer, Hale
    Akin, Mete
    Albayrak, Bulent
    Sen, Ilker
    Alkim, Huseyin
    Uyanikoglu, Ahmet
    Irak, Kader
    Oztaskin, Sinem
    Ugurlu, Cagri Burak
    Gunes, Sevkican
    Gurel, Selim
    Nuriyev, Kenan
    Inci, Ismail
    Kacar, Sabite
    Dincer, Dinc
    Doganay, Levent
    Gokturk, Huseyin Savas
    Mert, Ali
    Cosar, Arif Mansur
    Dursun, Hakan
    Atalay, Roni
    Akbulut, Sabiye
    Balkan, Yasemin
    Koklu, Hayrettin
    Simsek, Halis
    Ozdogan, Osman
    Coban, Mehmet
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2020, 31 (12): : 883 - 893
  • [50] Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients
    Khatri, Amit
    Mensing, Sven
    Podsadecki, Thomas
    Awni, Walid
    Menon, Rajeev
    Dutta, Sandeep
    CLINICAL DRUG INVESTIGATION, 2016, 36 (08) : 625 - 635
12345